Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background And Aims: Mucosal healing is associated with favourable therapeutic outcomes in patients with ulcerative colitis [UC]. We investigated whether adalimumab concentrations during induction therapy are associated with short-term mucosal healing [STMH] in UC patients.
Methods: This was a retrospective, single-centre study including consecutive UC patients treated with adalimumab from June 2005 to May 2014, who underwent an endoscopy both at baseline and after induction therapy [weeks 8-14] and at least one serum sample available at week 2 and/or week 4. STMH was defined as Mayo endoscopic sub-score of ≤1 with a baseline sub-score of ≥2. Adalimumab concentrations were evaluated using an in-house developed enzyme-linked immunosorbent assay.
Results: The study population consisted of 43 patients, the majority of whom [n = 38] were prior infliximab failures; the rest showed primary non-response [PNR, n = 5]. Twelve patients [27.9%] achieved STMH. Patients with STMH had higher adalimumab concentrations at week 4 compared to those without [10.6 vs 7.4 μg/ml, p = 0.014]. A receiver operating characteristic [ROC] analysis identified an adalimumab concentration threshold at week 4 of 9.4 μg/ml (area under the ROC curve [AUROC]: 0.778) and 7.5 μg/ml [AUROC: 0.798], after excluding patients with PNR to infliximab, to be associated with STMH. Multiple logistic regression analysis, after excluding patients with PNR to infliximab, identified adalimumab concentration ≥7.5 μg/ml at week 4 (odds ratio [OR]: 15.7; 95% confidence interval [CI]: 1.3-185; p = 0.029) and baseline endoscopic Mayo score 3 [OR: 0.13; 95% CI: 0.02-0.98; p = 0.047] as factors independently associated with STMH.
Conclusions: This study, reflecting real-life clinical practice, demonstrated that post-induction adalimumab concentrations are associated with STMH, while higher baseline mucosal inflammation is related to lack of STMH in UC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/ecco-jcc/jjw122 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Real-World Adalimumab Trough Levels, Antidrug Antibody Levels, and Disease Activity in Rheumatoid Arthritis.
Ther Drug Monit
August 2025
Department of Hospital Pharmacy, Maasstad Hospital, Rotterdam, the Netherlands.
Background: The association between adalimumab trough levels and disease activity was evaluated in a real-world population with rheumatoid arthritis (RA). The distribution of adalimumab serum levels, proportion of patients with therapeutic exposure to adalimumab, and the presence of antidrug antibodies (ADAs) were explored to determine the utility of therapeutic drug monitoring in RA.
Methods: A cross-sectional study was conducted among 72 patients with RA who were treated with adalimumab at Maasstad Hospital between May 2022 and March 2023.
Background: CT-P17 (Yuflyma), a biosimilar to adalimumab (Humira), offers a cost-effective alternative with improved access for individuals with immune-mediated inflammatory diseases (IMIDs). Assessing patient experience with autoinjector usability and comfort is crucial for ensuring adherence and satisfaction. This study is the first to evaluate patient-reported satisfaction and safety of CT-P17 specifically in people with Crohn's disease (CD).
View Article and Find Full Text PDFA switch to infliximab may be more effective than ustekinumab following adalimumab pharmacodynamic failure in paediatric patients with Crohn's disease.
Dig Liver Dis
September 2025
Juliet Keidan Institute of Paediatric Gastroenterology, Hepatology and Nutrition, The Eisenberg R&D Authority, Shaare Zedek Medical Centre, The Hebrew University, Jerusalem, Israel; The paediatric gastroenterology unit, Kaplan Medical Centre, Rehovot, Israel.
Background: Loss of response (LOR) to anti-TNFα in patients with Crohn's disease (CD) is not uncommon. A particular challenge is pharmacodynamic LOR (inflammatory activity persisting despite adequate trough concentrations, TC).
Aims: To explore the outcomes of paediatric patients with CD following adalimumab pharmacodynamic failure.
Influence of Pharmacokinetic-Pharmacodynamic Failure Mechanisms on Outcomes in Biologic Therapy Sequencing in Inflammatory Bowel Disease: A Retrospective Cohort Study.
BioDrugs
September 2025
Department of Gastroenterology, Herlev and Gentofte Hospital, Herlev, Denmark.
Background: Increasing therapeutic options for inflammatory bowel disease calls for tools to aid choice of sequencing. We investigated if pharmacokinetic (PK) and pharmacodynamic (PD) failure mechanisms prompting therapy change influenced subsequent outcomes when switching to a different biologic drug class.
Methods: Retrospective single-center cohort study including patients treated first with tumor necrosis factor (TNF) inhibitors, followed by vedolizumab, and then ustekinumab.
Multiple Switches Between Adalimumab-fkjp and Reference Adalimumab in Moderate-to-Severe Chronic Plaque Psoriasis: A Multicenter, Double-Blind, Parallel Group, Randomized Clinical Trial for Interchangeability.
Adv Ther
August 2025
Clinical Development and Medical Affairs, Biocon Biologics UK Ltd, London, WC2B 5 AH, UK.
Introduction: This study was conducted to fulfill the FDA requirement for the designation of adalimumab-fkjp, an FDA-approved biosimilar, as an 'interchangeable' biosimilar to the reference adalimumab. The primary objective was to evaluate the interchangeability of adalimumab-fkjp (low concentration, 40 mg/0.8 mL) with reference adalimumab (high concentration, 40 mg/0.
View Article and Find Full Text PDF